Wellcome Trust MRC Cambridge Stem Cell Institute
Lead Research Organisation:
University of Cambridge
Department Name: UNLISTED
Abstract
Wellcome Trust MRC Cambridge Stem Cell Institute
Director: Professor Austin Smith, University of Cambridge
Stem cell science is providing a stream of new knowledge about how our bodies are made and maintained. This research brings the promise that better understanding of stem cells will lead to future medical applications. Treatments may come through several routes. First, human stem cells grown in the laboratory can be used to produce experimental models of diseased tissues and to test therapeutic drugs. Second, some disorders, including forms of cancer, involve abnormal behaviour of stem cells. As we learn how to control stem cells it may become possible to correct these faults. Third, finding how to prevent a decline in numbers and activity of stem cells may help to maintain health during ageing. Finally, stem cells could be used to renew damaged tissues and replace missing cells in certain disorders.
The Cambridge Stem Cell Institute is being formed to explore and define the properties of stem cells and establish their true medical potential. Leading research scientists, technology specialists and doctors will work side by side to create a world-leading centre of excellence in stem cell biology and medicine. The Institute will also collaborate with bioindustry and will provide high level training for young researchers from around the world.
Director: Professor Austin Smith, University of Cambridge
Stem cell science is providing a stream of new knowledge about how our bodies are made and maintained. This research brings the promise that better understanding of stem cells will lead to future medical applications. Treatments may come through several routes. First, human stem cells grown in the laboratory can be used to produce experimental models of diseased tissues and to test therapeutic drugs. Second, some disorders, including forms of cancer, involve abnormal behaviour of stem cells. As we learn how to control stem cells it may become possible to correct these faults. Third, finding how to prevent a decline in numbers and activity of stem cells may help to maintain health during ageing. Finally, stem cells could be used to renew damaged tissues and replace missing cells in certain disorders.
The Cambridge Stem Cell Institute is being formed to explore and define the properties of stem cells and establish their true medical potential. Leading research scientists, technology specialists and doctors will work side by side to create a world-leading centre of excellence in stem cell biology and medicine. The Institute will also collaborate with bioindustry and will provide high level training for young researchers from around the world.
Technical Summary
This award is to facilitate creation of a world-leading centre for fundamental and translational stem cell research at the University of Cambridge. The Cambridge Stem Cell Institute (SCI) will build upon previous Wellcome Trust and Medical Research Council funding by drawing together 30 research teams into a cohesive centre. These groups will ultimately be co-located in a purpose-designed 8000m2 facility to be constructed on the Cambridge Biomedical Research Campus. The overall objective of this proposal is to define the potential of stem cell biology for human medicine. This relies on assembling a critical mass of talent in fundamental stem cell science alongside investigators focussed on translation to medical applications. The Cambridge Stem Cell Institute will be broad-based, well-resourced and intellectually invigorating. Cross-fertilisation between pluripotent and tissue stem cell biology will stimulate basic discoveries and increase capacity to address issues of human health and disease. Based on acquiring a deep understanding of stem cells allied with a clinical perspective, Institute scientists will pioneer innovative therapeutic approaches to unmet medical needs. Platform technologies supported by a Centre grant will enable SCI to recruit and retain the most talented investigators and empower them to make ground-breaking advances in understanding stem cells and their medical applications. Fundamental research will focus at the molecular level on mechanisms of self-renewal, commitment, differentiation and reprogramming. Functional studies will address the role of stem cells in development, repair, ageing, physiology and pathologies including cancer. Disease-specific induced pluripotent stem cells will be exploited to unravel mechanisms of cellular pathogenesis and define drug targets. Strategies to mobilise endogenous stem cells for regeneration will be evaluated in animal models and in the clinic as will approaches based on cell transplantation. The Institute will provide comprehensive training in embryonic and adult stem cell biology and will seek, and offer unique opportunities for, bioindustry interaction and collaboration.
Objectives
The objectives for SCI are:
(i) to uncover fundamental principles of stem cell identity, regulation and function;
(ii) to translate this knowledge into new tools for drug discovery and diagnostics;
(iii) to pioneer therapeutic approaches based on recruitment of endogenous stem cells and/or cell transplantation strategies.
Objectives
The objectives for SCI are:
(i) to uncover fundamental principles of stem cell identity, regulation and function;
(ii) to translate this knowledge into new tools for drug discovery and diagnostics;
(iii) to pioneer therapeutic approaches based on recruitment of endogenous stem cells and/or cell transplantation strategies.
Organisations
- University of Cambridge (Lead Research Organisation)
- University of Zurich (Collaboration)
- ETH Zurich (Collaboration)
- LOUGHBOROUGH UNIVERSITY (Collaboration)
- The Hospital for Sick Children (SickKids) (Collaboration)
- CN Bio Innovations Ltd (Collaboration)
- Friedrich Miescher Institute for Biomedical Research (FMI) (Collaboration)
- Bellvitge Biomedical Research Institute (Collaboration)
- Baylor College of Medicine (Collaboration)
- Keio University (Collaboration)
- Norwegian University of Science and Technology (NTNU) (Collaboration)
- Microsoft Research (Collaboration)
- Chinese Academy of Medical Sciences (CAMS) (Collaboration)
- Dando, Weiss & Colucci Ltd (Collaboration)
- Cancer Research UK Cambridge Institute (Collaboration)
- University Libre Bruxelles (Université Libre de Bruxelles ULB) (Collaboration)
- NsGene A/S (Collaboration)
- German Cancer Research Center (Collaboration)
- Johns Hopkins University (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- Icahn School of Medicine at Mount Sinai (Collaboration)
- Pasteur Institute, Paris (Collaboration)
- European Molecular Biology Laboratory (Collaboration)
- The Walter and Eliza Hall Institute of Medical Research (WEHI) (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- Central Institute for Experimental Animals (CIEA) (Collaboration)
- Francis Crick Institute (Collaboration)
- University of Copenhagen (Collaboration)
- British Council (Collaboration)
- StemCells, Inc. (Collaboration)
- Newcastle University (Collaboration)
- Erasmus MC (Collaboration)
- Austrian Academy of Sciences (Collaboration)
- Stemcell Technologies (Collaboration)
- NeuroNova AB (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- Gaslini Children's Hospital (Collaboration)
- Spanish National Centre for Cardiovascular Research (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Academy of Sciences of the Czech Republic (Collaboration)
- Acerta (Collaboration)
- Medical University of Wurzburg (Collaboration)
- IRCCS Oasi Maria SS (Collaboration)
- Galvani Bioelectronics Ltd (Collaboration)
- Radboud University Nijmegen Medical Center (Collaboration)
- Ferring Pharmaceuticals (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Medical College of Wisconsin (Collaboration)
- Domainex (Collaboration)
- Kymab (Collaboration)
- Yale University (Collaboration)
- Autolus Limited (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- UNIVERSITY OF DUNDEE (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- PLATOD (Collaboration)
- California Institute of Technology (Collaboration)
- DefiniGEN (Collaboration)
- University of Basel (Collaboration)
- University of Navarra Clinic (Collaboration)
- Penn State University (Collaboration)
- PhoreMost (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Lund University (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- AstraZeneca (Collaboration)
- Netherlands Cancer Institute (NKI) (Collaboration)
- University of Leipzig (Collaboration)
- University of Salento (Collaboration)
- RIKEN (Collaboration)
- Bit.Bio (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Mount Sinai Hospital (USA) (Collaboration)
- University of Bristol (Collaboration)
- Uniformed Services University of the Health Services (Collaboration)
- University of Buenos Aires (Collaboration)
- Babraham Institute (Collaboration)
- Korea Advanced Institute of Science and Technology (KAIST) (Collaboration)
- Sapio (Collaboration)
- National Institute for Health Research (Collaboration)
- University Hospital Zürich (Collaboration)
- Trinity College Dublin (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- University of California, Davis (Collaboration)
- University of Sussex (Collaboration)
- Tokyo Electron (Collaboration)
- Swiss Federal Institute of Technology in Lausanne (EPFL) (Collaboration)
- Cornell University (Collaboration)
- Tohoku University (Collaboration)
- University Medical Center Gronigen (Collaboration)
- CellCentric Ltd (Collaboration)
- Karolinska Institute (Collaboration)
- University Hospital of Basel (Collaboration)
- Cambridge Design Partnership (Collaboration)
- University of California, San Francisco (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Centre for Genomic Regulation (CRG) (Collaboration)
- University of Kyoto (Collaboration)
- Kumamoto University (Collaboration)
- Stem Cell Technologies (Collaboration)
- École Normale Supérieure, Paris (Collaboration)
- Helmholtz Association of German Research Centres (Collaboration)
- Numedicus Limited (Collaboration)
- Center of Regenerative Medicine in Barcelona (Collaboration)
- EMBL European Bioinformatics Institute (EMBL - EBI) (Collaboration)
- Leiden University Medical Center (Collaboration)
- University of Sheffield (Collaboration)
- Alternative Energies and Atomic Energy Commission (CEA) (Collaboration)
- University of Bath (Collaboration)
- Hebrew University of Jerusalem (Collaboration)
- University of Hawaii (Collaboration)
- University Medical Center Utrecht (UMC) (Collaboration)
- Cell Guidance Systems Ltd (Collaboration)
- Hemoshear Therapeutics (Collaboration)
- Claudius Regaud Hospital (Collaboration)
- Agency for Science, Technology and Research (A*STAR) (Collaboration)
- Biogen (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- Royal Netherlands Academy of Arts and Sciences (Collaboration)
- University of Kumamoto (Collaboration)
- San Raffaele Hospital (Collaboration)
- Oxford Gene Technology (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Tampere University of Technology (Collaboration)
- University of Paris - Descartes (Collaboration)
- University of Galway (Collaboration)
- Miltenyi Biotec GmBH (Collaboration)
- The University of Texas at San Antonio (Collaboration)
- Cancer Research UK (Collaboration)
- University Hospital Carl Gustav Carus Dresden (Collaboration)
- Memorial Sloan Kettering Cancer Center (Collaboration)
- Boston University (Collaboration)
- Research Network Services (RNSL) Ltd Berlin (Collaboration)
- Chinese Academy of Sciences (Collaboration)
- Life and Brain GmbH (Collaboration)
- Institute of Biomedical Imagery (I2BM) (Collaboration)
- Gustave-Roussy Institute (Collaboration)
- Justus Liebig University Giessen (Collaboration)
- Free University of Amsterdam (Collaboration)
- University of Georgia (Collaboration)
- University of Toronto (Collaboration)
- European Institute of Oncology (IEO) (Collaboration)
- UNIVERSITY OF BRITISH COLUMBIA (Collaboration)
- Weizmann Institute of Science (Collaboration)
- ROYAL PAPWORTH HOSPITAL NHS FOUNDATION TRUST (Collaboration)
- Cell Therapy Catapult (Collaboration)
- University of Oslo (Collaboration)
- University at Buffalo (Collaboration)
- UK Regenerative Medicine Platform (Collaboration)
- Novo Nordisk (Collaboration)
- University of Groningen (Collaboration)
- Institute of Genetics and Molecular and Cellular Biology (IGBMC) (Collaboration)
- UK Clinical Research Collaboration (Collaboration)
- Max Planck Society (Collaboration)
- Albert Einstein College of Medicine (Collaboration)
- Cardiff University (Collaboration)
- Pfizer Ltd (Collaboration)
- Technical University of Dresden (Collaboration)
- University Health Network (UHN) (Collaboration)
- UNSW Sydney (Collaboration)
- Roche Pharmaceuticals (Collaboration)
- Swiss Institute of Bioinformatics (SIB) (Collaboration)
- University of Helsinki (Collaboration)
- University of Valencia (Collaboration)
- University of Queensland (Collaboration)
- University of Kentucky (Collaboration)
- JDRF Center for Beta Cell Therapy in Diabetes (Collaboration)
- University of Milan (Collaboration)
- Sheba Medical Centre (Collaboration)
- University of Manchester (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- McGill University (Collaboration)
- Washington University in St. Louis (Collaboration)
- University of Veterinary Medicine Vienna (Collaboration)
- Hospital Son Espases (Collaboration)
- University of Turku (Collaboration)
- Technical University of Denmark (Collaboration)
- University of Vermont (Collaboration)
- Ministry of the Environment (Collaboration)
- Royal Institute of Technology (Collaboration)
- University of Leuven (Collaboration)
- University of Washington (Collaboration)
- University of Bonn (Collaboration)
People |
ORCID iD |
Publications
Mascetti VL
(2016)
Contributions of Mammalian Chimeras to Pluripotent Stem Cell Research.
in Cell stem cell
Morrison G
(2016)
Convergence of cMyc and ß-catenin on Tcf7l1 enables endoderm specification.
in The EMBO journal
Rheinlaender J
(2020)
Cortical cell stiffness is independent of substrate mechanics.
in Nature materials
Rheinlaender J
(2020)
Cortical cell stiffness is independent of substrate mechanics.
Green T
(2016)
Costs of haematological disease high and rising.
in The Lancet. Haematology
Göttgens B
(2015)
Creating cellular diversity through transcription factor competition.
in The EMBO journal
Wahlestedt M
(2017)
Critical Modulation of Hematopoietic Lineage Fate by Hepatic Leukemia Factor.
Wahlestedt M
(2017)
Critical Modulation of Hematopoietic Lineage Fate by Hepatic Leukemia Factor.
in Cell reports
Wahlestedt M
(2014)
Critical modulation of hematopoietic lineage fate by the PAR/bZIP transcription factor hepatic leukemia factor
in Experimental Hematology
Baker AM
(2019)
Crypt fusion as a homeostatic mechanism in the human colon.
in Gut
Baker A
(2019)
Crypt fusion as a homeostatic mechanism in the human colon.
Broutier L
(2016)
Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation.
in Nature protocols
Blair K
(2012)
Culture parameters for stable expansion, genetic modification and germline transmission of rat pluripotent stem cells.
in Biology open
Park HJ
(2016)
Cytokine-induced megakaryocytic differentiation is regulated by genome-wide loss of a uSTAT transcriptional program.
in The EMBO journal
Gkatza NA
(2019)
Cytosine-5 RNA methylation links protein synthesis to cell metabolism.
in PLoS biology
Flores JV
(2017)
Cytosine-5 RNA Methylation Regulates Neural Stem Cell Differentiation and Motility.
in Stem cell reports
Golan K
(2018)
Daily Onset of Light and Darkness Differentially Controls Hematopoietic Stem Cell Differentiation and Maintenance.
in Cell stem cell
Popescu D
(2019)
Decoding human fetal liver haematopoiesis.
Popescu DM
(2019)
Decoding human fetal liver haematopoiesis.
in Nature
Moignard V
(2015)
Decoding the regulatory network of early blood development from single-cell gene expression measurements.
in Nature biotechnology
Moignard V
(2014)
Decoding the transcriptional program for blood development from whole tissue single-cell gene expression measurements
in Experimental Hematology
Van Steenwinckel J
(2019)
Decreased microglial Wnt/ß-catenin signalling drives microglial pro-inflammatory activation in the developing brain.
in Brain : a journal of neurology
Van Haute L
(2016)
Deficient methylation and formylation of mt-tRNA(Met) wobble cytosine in a patient carrying mutations in NSUN3.
in Nature communications
Dunn SJ
(2014)
Defining an essential transcription factor program for naïve pluripotency.
in Science (New York, N.Y.)
Sznurkowska MK
(2018)
Defining Lineage Potential and Fate Behavior of Precursors during Pancreas Development.
in Developmental cell
Ibarra-Soria X
(2018)
Defining murine organogenesis at single-cell resolution reveals a role for the leukotriene pathway in regulating blood progenitor formation.
in Nature cell biology
Williams-Gray C
(2017)
Defining PD subtypes - a step toward personalized management?
Aragona M
(2017)
Defining stem cell dynamics and migration during wound healing in mouse skin epidermis.
in Nature communications
Gottgens B
(2015)
Defining stem cells and regulatory networks by single cell profiling
in Experimental Hematology
Sánchez-Danés A
(2016)
Defining the clonal dynamics leading to mouse skin tumour initiation.
Sánchez-Danés A
(2016)
Defining the clonal dynamics leading to mouse skin tumour initiation.
in Nature
Dekoninck S
(2020)
Defining the Design Principles of Skin Epidermis Postnatal Growth.
Dekoninck S
(2020)
Defining the Design Principles of Skin Epidermis Postnatal Growth.
in Cell
Lescroart F
(2018)
Defining the earliest step of cardiovascular lineage segregation by single-cell RNA-seq.
in Science (New York, N.Y.)
| Title | Stem Cell Revolutions |
| Description | Austin Smith provided the voice over for the Stem Cell Revolutions film. Featuring beautiful hand-drawn animations and interviews with leading stem cell scientists, Stem Cell Revolutions charts the history and scientific evolution of stem cell research - from the earliest experiments that first revealed stem cells in the body, to leading current scientific and clinical developments |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2013 |
| Impact | Increased understanding of Stem Cell Biology on an international scale |
| URL | http://www.stemcellrevolutions.com/watch |
| Description | Advisory board member for: Izmir Biomedicine and Genome Center, Dokuz Eylul University, Turkey |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | AstraZeneca, Stem Cell & Primary Cell Scientific Advisory Board, Sweden |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Briefing of Policy Advisor |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Briefing of Wellcome Trust Policy Advisor |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Briefing of Wellcome Trust Policy Advisor - Dr Alexis Gilbert |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | CDB |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Cell Fate and Cancer Programme, Centre for Genomic Regulation, Barcelona, Spain |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Cell Therapy Catapult Academic Advisory Board, London, UK |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Cell and Gene Therapy Catapult Scientific Advisory Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | CiRA Symposium, Kyoto |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | CiRA Symposium, Kyoto |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Global COE programme, Kyoto |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Guideline Title | Guideline for the treatment of chronic lymphocytic leukaemia |
| Description | Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15460 |
| Description | Health Education England's Genomic Education Programme's Competency Framework Review |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | Health Education England's Genomic Education Programme's Competency Framework Review for obtaining informed consent for genomic testin. |
| Description | ISSCR - keynote speaker |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | ISSCR Advisory Board |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | ISSCR Board of Directors Meeting |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | International Scientific Advisory Board Annual Meeting 2014 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | MEP Briefing |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | MEP Forum - Brussels |
| Geographic Reach | Europe |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Pontifical Academy of Sciences |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Riken Advisory Committee |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Riken Advisory Council |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Royal College of Surgeons (Ludovic Vallier) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.youtube.com/watch?v=wnYyJxXhkLE&t=13507s |
| Description | UKSCB Advisory Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Wellcome Trust Sanger Institute Cellular Genetics Programme |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | (HARMONY PLUS) - HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY - PLUS |
| Amount | € 11,882,669 (EUR) |
| Funding ID | 945406 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 09/2020 |
| End | 09/2023 |
| Description | (NSC-Reconstruct) - Novel Strategies for Cell-based Neural Reconstruction |
| Amount | € 8,169,231 (EUR) |
| Funding ID | 874758 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2020 |
| End | 12/2023 |
| Description | 3RD SCIENTIFIC WORKSHOP |
| Amount | £5,000 (CLF) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 06/2019 |
| Description | 819956 PATRES-MDS - Pathogenesis and treatment of splicing factor mutant myelodysplastic syndromes |
| Amount | € 1,999,771 (EUR) |
| Funding ID | 819956 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 04/2019 |
| End | 04/2024 |
| Description | 886474 ChRONAM-H - Chromatin Regulation Of Normal And Malignant Haematopoiesis |
| Amount | € 212,934 (EUR) |
| Funding ID | 886474 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 09/2020 |
| End | 09/2022 |
| Description | A Reference Cell Atlas of Human Liver Diversity Over a Lifespan |
| Amount | £150,000 (GBP) |
| Organisation | Chan Zuckerberg Initiative |
| Sector | Private |
| Country | United States |
| Start | 08/2019 |
| End | 08/2021 |
| Description | Addenbrookes Charitable Trust award of Consumables for Dr. K.Kurian to work within Biochemistry: Stem Cell Institute |
| Amount | £10,000 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Advanced Clinician Scientist Fellowship (Simon Buczacki) |
| Amount | £1,500,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2023 |
| Description | Advanced grant: New-Chol: Development of new therapies against Cholangiopathies (Ludovic Vallier) |
| Amount | £2,200,000 (GBP) |
| Funding ID | 741707 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 12/2017 |
| End | 11/2022 |
| Description | Age related changes in alternative splicing in oligodendrocyte progenitor cells (Robin Franklin) |
| Amount | £591,058 (GBP) |
| Organisation | Biogen |
| Sector | Private |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 06/2021 |
| Description | Authentication of primate pluripotent stem cells for chimaera formation |
| Amount | £530,915 (GBP) |
| Funding ID | MR/S020845/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 02/2020 |
| Description | BB/H012737/1 Gene Targetting by homologous recombination in the Rat |
| Amount | £612,215 (GBP) |
| Funding ID | BB/H012737/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2011 |
| End | 05/2015 |
| Description | BBSRC Stem Cell Potency |
| Amount | £841,267 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2006 |
| End | 02/2008 |
| Description | BIG regulates the circadian clock and development (equipment) (Robin Franklin) |
| Amount | £251,744 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2023 |
| Description | Beit Memorial Fellowship for Medical Research |
| Amount | £126,043 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome-Beit Prize Fellowships |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2007 |
| End | 09/2010 |
| Description | BetaCellTherapy: Beta Cell Therapy in Diabetes |
| Amount | £823,424 (GBP) |
| Funding ID | 241883 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2010 |
| End | 12/2014 |
| Description | Biogenesis and bioengineering of human platelets |
| Amount | £593,451 (GBP) |
| Funding ID | 219472/A/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 02/2025 |
| Description | Bioinformatic analyses of chromatin remodelling during cell fate transitions in embryonic stem cells (Brian Hendrich) |
| Amount | £21,982 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 09/2018 |
| Description | Biotechnology for investigating cell fate choice |
| Amount | £1,660,723 (GBP) |
| Funding ID | 772798 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 03/2018 |
| End | 03/2023 |
| Description | Bronchiolar and Alveolar Organoids (Joo-Hyeon Lee) |
| Amount | £153,327 (GBP) |
| Organisation | AstraZeneca |
| Department | Astra Zeneca |
| Sector | Private |
| Country | United States |
| Start | 12/2017 |
| End | 12/2019 |
| Description | CALR mutations and human myeloproliferative neoplasms. |
| Amount | £2,000,004 (GBP) |
| Funding ID | 104710/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 10/2022 |
| Description | CHARACTERISATION OF ALTERED EPIGENETIC CELL STATES FOLLOWING LOSS OF CREBBP FUNCTION AND THEIR ROLE IN THE INDUCTION AND TREATMENT OF ALL |
| Amount | £1,219,270 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 05/2024 |
| Description | CHARACTERIZATION OF ZAP70-MEDIATED SIGNALLING PATHWAYS IN DI (Ingo Ringshausen) |
| Amount | £218,332 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | CHINA - UK STEM CELL SYMPOSIUM |
| Amount | £18,000 (GBP) |
| Organisation | British Council |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2019 |
| Description | CROSS TALK BETWEEN REPRESSIVE HISTONE MODIFICATIONS AND DNA METHYLATION IN THE PATHOGENESIS AND EVOLUTION OF MYELOID MALIGNANCIES |
| Amount | £240,282 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2021 |
| Description | Cambridge Biomedical Research Centre - funding for Cancer Molecular Diagnostic Laboratory |
| Amount | £1,175,000 (GBP) |
| Organisation | Cambridge University Hospitals NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2022 |
| Description | Cambridge Biomedical research Centre - funding for Cambridge Blood and Stem Cell Biobank |
| Amount | £1,061,140 (GBP) |
| Organisation | Cambridge University Hospitals NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2022 |
| Description | Cambridge Cancer Centre Studentship |
| Amount | £195,918 (GBP) |
| Organisation | Cambridge Cancer Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2020 |
| Description | Cambridge Doctoral Training Partnership |
| Amount | £96,736 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2021 |
| Description | Capturing formative pluripotency (Austin Smith) |
| Amount | £662,127 (GBP) |
| Funding ID | BB/P009867/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2020 |
| Description | Catherine Dubrowska consumables (Lee lab) |
| Amount | £39,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2021 |
| Description | Centre for Stem Cell Biology & Regenerative Medicine |
| Amount | £795,134 (GBP) |
| Funding ID | G0800784 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2009 |
| End | 12/2011 |
| Description | Characterisation of new human ES cell derived in novel |
| Amount | £55,624 (GBP) |
| Funding ID | 4-2005-821 |
| Organisation | Juvenile Diabetes Research Foundation (JDRF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2007 |
| End | 12/2007 |
| Description | Collaborative bursary MiRNA expression in brain cancer stem cells |
| Amount | £6,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Connecting Cambridge (Chrysa Kapeni) |
| Amount | £39,197 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 10/2018 |
| Description | Core Support for Wellcome Trust Centre for Stem Cell Research |
| Amount | £6,956,531 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2007 |
| End | 12/2011 |
| Description | Cystic Fibrosis Innovation Hub Award (Ludovic Vallier) |
| Amount | £145,000 (GBP) |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2023 |
| Description | DECIPHERING LEUKAEMOGENIC MECHANISMS BY INTEGRATED SYSTEMS-SCALE ANALYSIS |
| Amount | £299,538 (GBP) |
| Organisation | Bloodwise |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2022 |
| Description | DECIPHERING THE ROLE OF C/EBPX IN THE EVOLUTION OF HAEMATOLOGY (Bertie Gottgens) |
| Amount | £29,172 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 02/2019 |
| Description | DEVELOPMENT OF A LYMPHOMA-SPECIFIC MUTANT OPEN READING FRAME (MORF) LIBRARY |
| Amount | £34,400 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 06/2020 |
| Description | DEVELOPMENT OF NEW METHOD OF DIFFERENTIATION FOR HEPATOCYTES |
| Amount | £113,477 (GBP) |
| Organisation | DefiniGEN |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2021 |
| Description | Deciphering and overcoming epigenetic erosion at imprinted loci in mouse and human naive pluripotent stem cells |
| Amount | £417,766 (GBP) |
| Funding ID | BB/R018588/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 06/2022 |
| Description | Deciphering myeloid landscape of non-small cell lung cancer |
| Amount | £1,022,207 (GBP) |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Open Targets |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2022 |
| Description | Decoding the network logic for decoding pluripotency (Austin Smith) |
| Amount | £111,786 (GBP) |
| Funding ID | BB/P021573/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2019 |
| Description | Defining the Haematopoietic System through Integrated Multi-Scale Analysis (Bertie Gottgens) |
| Amount | £2,028,031 (GBP) |
| Funding ID | 206328 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2023 |
| Description | Defining the molecular consequences of mutations that disrupt early heart development (Bertie Gottgens) |
| Amount | £13,000 (GBP) |
| Organisation | Wiener-Anspach Foundation |
| Sector | Charity/Non Profit |
| Country | Belgium |
| Start | 09/2018 |
| End | 12/2020 |
| Description | Defining the prerequisites of naïve pluripotent human embryo cells for self-renewal in culture (Jenny Nichols) |
| Amount | £683,801 (GBP) |
| Funding ID | MR/P010423/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | Delimiting the stem cell phase boundary via time normalisation (Austin Smith) |
| Amount | £224,408 (GBP) |
| Organisation | The Leverhulme Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2019 |
| Description | Developing new models for the functional investigation of Lymphoma |
| Amount | £104,000 (GBP) |
| Organisation | Gilead Sciences, Inc. |
| Department | Gilead |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Druggable epigenetic control by modulation of a transcriptional master-regulator: switching neuroblastoma from a proliferative to a differentiation programme (Anna Philpott) |
| Amount | £1,600,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2023 |
| Description | ERC Advanced Grant: Myelin at the crossroads of Development and Disease (David Rowitch) |
| Amount | £1,785,714 (GBP) |
| Funding ID | 789054 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 09/2018 |
| End | 09/2023 |
| Description | ESTOOLS: Platforms for Biomedical Discovery with Human ES cells |
| Amount | £373,970 (GBP) |
| Funding ID | 18739 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 07/2006 |
| End | 07/2010 |
| Description | EURATRANS European large-scale functional genomics in the rat for translational research (10.5m euros across 19 participants) |
| Amount | £517,672 (GBP) |
| Funding ID | 241504 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 03/2010 |
| End | 09/2014 |
| Description | EUROSTEMCELL: European Consortium for Stem Cell Research (0.8m euros across 11 participants) |
| Amount | £6,457 (GBP) |
| Funding ID | 241878 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 03/2010 |
| End | 02/2015 |
| Description | EUROSTEMCELL: European Consortium for Stem Cell Research (0.8m euros across 11 participants) |
| Amount | £38,175 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 08/2006 |
| End | 01/2008 |
| Description | EUROSYSTEM European consortium for systematic stem Cell Biology (12m euros across 24 participants) |
| Amount | £1,184,402 (GBP) |
| Funding ID | 200720 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 03/2008 |
| End | 08/2012 |
| Description | Early Detection Markers for Gastroesophageal Cancer; a Proteomic Perspective of Epithelial-Stromal Crosstalk. |
| Amount | £248,437 (GBP) |
| Funding ID | 19-0192 |
| Organisation | Worldwide Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 04/2021 |
| Description | Elucidation of cellular and molecular mechanisms of lymphoma induction and evolution to identify therapeutic targets |
| Amount | £755,910 (GBP) |
| Funding ID | MR/R009708/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | Embryonic Stem Cells, Neural stem cells and Neurons |
| Amount | £102,527 (GBP) |
| Organisation | Fidelity Biosciences |
| Sector | Private |
| Country | United States |
| Start | 04/2007 |
| End | 05/2009 |
| Description | Engineered Cell Environment (Andrew McCaskie) |
| Amount | £416,196 (GBP) |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2023 |
| Description | Enhancer subversion and its role in the generation and maintenance of Acute Myeloid Leukaemia |
| Amount | £1,700,826 (GBP) |
| Funding ID | 25508 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2023 |
| Description | Fellowship for abroad - Dorian Forte |
| Amount | £113,822 (GBP) |
| Organisation | AIRC Foundation for Cancer Research in Italy |
| Sector | Public |
| Country | Italy |
| Start | 02/2018 |
| End | 01/2020 |
| Description | Generating platelets in vitro for the clinic: optimisation and added clinical efficacy |
| Amount | £474,809 (GBP) |
| Funding ID | MR/V005413/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2024 |
| Description | Generation of human iPSC- derived motor neurons and microglia to model ALS pathophysiology in a dish (Stefano Pluchino) |
| Amount | £7,800 (GBP) |
| Organisation | University of Montreal |
| Department | Montreal Neurological Institute |
| Sector | Hospitals |
| Country | Canada |
| Start | 01/2017 |
| End | 12/2017 |
| Description | Genetic screen to identify new target for NAFLD/NASH |
| Amount | £250,000 (GBP) |
| Organisation | University of Cambridge |
| Department | Milner Therapeutics Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2021 |
| Description | HARMONY - Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in hematology |
| Amount | £130,435 (GBP) |
| Funding ID | 116026 |
| Organisation | European Federation of Pharmaceutical Industries and Associations (EFPIA) |
| Sector | Private |
| Country | Belgium |
| Start | 01/2017 |
| End | 12/2021 |
| Description | HUMAN DEVELOPMENTAL BIOLOGY INITIATIVE |
| Amount | £1,770,671 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2024 |
| Description | Heterogeneity of the human epicardium: molecular determinants and functional consequences (Sanjay Sinha) |
| Amount | £185,375 (GBP) |
| Funding ID | PG/17/24/32886 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2019 |
| Description | Horizon2020 FTE grant |
| Amount | £2,641,920 (GBP) |
| Organisation | European Union |
| Sector | Public |
| Country | European Union (EU) |
| Start | 11/2017 |
| End | 12/2021 |
| Description | How does ageing affect remyelination potential? |
| Amount | £257,498 (GBP) |
| Organisation | Dr. Miriam and Sheldon G. Adelson Medical Research Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2017 |
| End | 09/2018 |
| Description | Human Cell Atlas (Bertie Gottgens) |
| Amount | £390,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 04/2021 |
| Description | IDENTIFICATION AND FUNCTIONAL VALIDATION OF GENES INVOLVED IN NON-ALCOHOLIC FATTY LIVER DISEASE |
| Amount | £248,669 (GBP) |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Open Targets |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2022 |
| Description | IDENTIFICATION AND VALIDATION OF TRACTABLE TARGETS FOR REJUVENATION |
| Amount | £516,000 (GBP) |
| Organisation | Dementia Discovery Fund |
| Sector | Private |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 08/2022 |
| Description | IMAGING REMEYLINATION IN THE CENTRAL NERVOUS SYSTEM |
| Amount | £282,280 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 01/2022 |
| Description | Identification and characterisation of metabolic pathways as determinants of drug responses in acute myloid leukaemia (AML) - Paolo Gallipoli |
| Amount | £103,703 (GBP) |
| Organisation | American Society of Haematology (ASH) |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 07/2018 |
| End | 03/2020 |
| Description | Identification and functional validation of genes involved in non-alcoholic steatohepatitis liver disease |
| Amount | £650,000 (GBP) |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Open Targets |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2020 |
| Description | Identification of disease modifying treatments for PD, using patient-derived induced neurons (Roger Barker) |
| Amount | £127,246 (GBP) |
| Organisation | Cure Parkinson's Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2019 |
| Description | Identification of pathogenic autoantibodies in stiff person syndrome (Thora Karadottir) |
| Amount | £23,256 (GBP) |
| Organisation | National Organization for Rare Disorders (NORD) |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2018 |
| End | 10/2020 |
| Description | Impact of Cell & Gene Therapy onthe function and molecular regulation of haematopoietic stem cells (Elisa Laurenti) |
| Amount | £136,627 (GBP) |
| Funding ID | 1942750 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2021 |
| Description | Improving haematopoietic reconstitution in blood stem cell transplantation procedures through the regulation of stem cells and their niches |
| Amount | £634,921 (GBP) |
| Funding ID | MR/V005421/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2023 |
| Description | Interdisciplinary prize: Generation and transplantation of a bioengineered human bile duct (Ludovic Vallier) |
| Amount | £250,000 (GBP) |
| Funding ID | M787 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 08/2020 |
| Description | Isaac Newton Trust |
| Amount | £37,297 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Isaac Newton Trust |
| Amount | £29,346 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 05/2019 |
| Description | Japanese Partnership |
| Amount | £56,594 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2010 |
| End | 06/2014 |
| Description | Junior Research Grant |
| Amount | € 100,000 (EUR) |
| Funding ID | RG65 |
| Organisation | European Hematology Association (EHA) |
| Sector | Charity/Non Profit |
| Country | Netherlands |
| Start | 09/2020 |
| End | 09/2022 |
| Description | Kelly Evans iCase Studentship with AstraZeneca (Lee Lab) |
| Amount | £130,212 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2021 |
| Description | LEVERAGING HYPOXIA-INDUCED EPIGENETIC HETEROGENEITY IN LUNG CANCER |
| Amount | £37,500 (GBP) |
| Organisation | Hope Funds for Cancer research |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 06/2019 |
| End | 06/2021 |
| Description | MAHA ALFAIDI - PHD FEES AND CONSUMABLES |
| Amount | £34,595 (GBP) |
| Organisation | Saudi Arabian Cultural Bureau |
| Sector | Public |
| Country | Canada |
| Start | 03/2019 |
| End | 05/2020 |
| Description | MRC Confidence in Concept - University of Cambridge: Improving gene therapy protocol efficacy by modulating haematopoietic stem cell exit from quiescence (Elisa Laurenti) |
| Amount | £64,094 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 10/2018 |
| Description | MRC Stem Cell Career Development Fellowship |
| Amount | £279,872 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2008 |
| End | 07/2011 |
| Description | Mathematical Genomics and Medicine Programme PhD studentship |
| Amount | £40,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2020 |
| Description | Mathematical clonal analysis of cancer initiating cells in homeostasis and injury-repair using modified Rosa-confetti alleles in diverse tissues |
| Amount | £386,713 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2020 |
| Description | Mechanisms of adhesion-dependent haematopoietic transdetermination |
| Amount | £575,124 (GBP) |
| Funding ID | MR/T028343/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 07/2024 |
| Description | Mechanisms of lineage restriction in development and reprogramming. |
| Amount | £1,998,310 (GBP) |
| Funding ID | 212253/Z/18/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2026 |
| Description | Mesenchymal contribution to early oesophagael cancer |
| Amount | £449,996 (GBP) |
| Funding ID | MR/P019013/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 04/2020 |
| Description | Microenvironmental metabolic regulation in myeloid malignancies (Simon Mendez-Ferrer) |
| Amount | £148,761 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2022 |
| Description | NeuroStemcell Project - European consortium for stem Cell therapy |
| Amount | £652,985 (GBP) |
| Funding ID | 222943 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 12/2008 |
| End | 05/2013 |
| Description | Neuronal Regulation of CNS Myelin Plasticity (Thora Karadottir) |
| Amount | £1,769,672 (GBP) |
| Funding ID | 771411 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 06/2018 |
| End | 05/2023 |
| Description | New therapeutic strategies for Marfan and other genetically-triggered aortic aneurysm syndromes (Sanjay Sinha) |
| Amount | £1,281,390 (GBP) |
| Funding ID | RG/17/5/32936 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2022 |
| Description | Novel approach to model Non-Alcoholic Fatty Liver Disease using human Pluripotent Stem Cells. |
| Amount | £115,646 (GBP) |
| Funding ID | NC/R001987/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 05/2020 |
| Description | Novel organoid models for chronic lung disease |
| Amount | £25,000 (GBP) |
| Organisation | British Lung Foundation (BLF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 03/2019 |
| Description | OESOPHAGEAL CELL PLASTICITY IN RESPONSE TO INJURY AND EARLY Tumorigenesis |
| Amount | £173,004 (GBP) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 05/2019 |
| End | 05/2021 |
| Description | Ole Wiskow Studentship |
| Amount | £22,500 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 01/2007 |
| End | 12/2009 |
| Description | OncoLive | Optogenetic control and measurement of oncogenic mutations and signalling in organoid cultures for the biophysical modelling of early oncog |
| Amount | £245,019 (GBP) |
| Funding ID | NS/A000077/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 07/2022 |
| Description | Personalised cell-based and iron chelator therapies for hypomyelinating leukodystrophy (David Rowitch) |
| Amount | £84,447 (GBP) |
| Funding ID | 2431 |
| Organisation | Action Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2018 |
| Description | PhD Programme for Clinicians |
| Amount | £49,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 10/2020 |
| Description | PhD Studentship |
| Amount | £49,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2019 |
| End | 12/2022 |
| Description | PhD Studentship |
| Amount | £87,552 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 03/2023 |
| Description | PhD Studentship |
| Amount | £77,511 (GBP) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 08/2019 |
| End | 08/2023 |
| Description | PhD Studentship |
| Amount | £92,000 (GBP) |
| Organisation | National Institute for Health Research (NIHR) |
| Department | Oxford-Cambridge Scholars Program |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2023 |
| Description | PhD Studentship |
| Amount | £70,038 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2022 |
| Description | Plasticity of the Pluripotency Network |
| Amount | € 2,499,970 (EUR) |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 01/2020 |
| End | 12/2024 |
| Description | Platform to phenotype liver metabolic disorders |
| Amount | £50,000 (GBP) |
| Funding ID | NC/T2T0419 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 04/2020 |
| Description | Plurimes - Pluripotent Stem Cell Resources for Mesodermal Medicine |
| Amount | £1,511,268 (GBP) |
| Funding ID | 602423 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 02/2014 |
| End | 01/2018 |
| Description | Positive selection CRISPR screening in primary human B cells to elucidate the pathogenesis of DLBCL (Daniel Hodson) |
| Amount | £208,900 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2020 |
| Description | Precision Transgenesis in Rats via Embryonic Stem Cells |
| Amount | £52,827 (GBP) |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 07/2006 |
| End | 01/2009 |
| Description | Programme Grant |
| Amount | £300,000 (GBP) |
| Organisation | Bloodwise |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 05/2020 |
| Description | Project Grant - An investigation of the pre-clinical evolution of TET2-mutant myeloid neoplasms (George Vassiliou) |
| Amount | £227,397 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2021 |
| Description | Provision for public engagement - Stem Cell Institute Public Engagement Officer |
| Amount | £171,011 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 06/2017 |
| Description | Re-defining the paradigm of X-chromosome inactivation |
| Amount | £416,235 (GBP) |
| Funding ID | MR/R017735/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 06/2022 |
| Description | Regulation and function of the pluripotency determinant Nanaog |
| Amount | £844,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2006 |
| End | 10/2010 |
| Description | Regulation of Self Renewal, Commitment and Differentiation in Brain Cancer Cells |
| Amount | £177,218 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2008 |
| End | 05/2011 |
| Description | Repurposing AMPAkines for enhancing myelin regeneration in Multiple Sclerosis |
| Amount | £130,000 (GBP) |
| Funding ID | 204488/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 07/2018 |
| Description | Repurposing glutamate modulators for enhancing myelin regene |
| Amount | £70,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 10/2017 |
| Description | Resolving white matter disfunction in Alzheimer's disease with patient specific cell |
| Amount | £38,373 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 07/2018 |
| Description | Royal Society Research Professorship |
| Amount | £791,000 (GBP) |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2023 |
| Description | Senior Cancer Research Fellowship (George Vassiliou) |
| Amount | £1,900,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 07/2023 |
| Description | Senior Clinical Fellowship: Human ESC-derived epicardium to promote cardiac regeneration and remusculation |
| Amount | £927,088 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 07/2023 |
| Description | Single cell isolation from heterogeneous normal and malignant cell populations |
| Amount | £50,000 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 06/2018 |
| Description | Statistical physics of cell fate choice |
| Amount | £40,000 (GBP) |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2019 |
| Description | Steering Embryonic Stem Cells towards Pancreatic |
| Amount | £43,902 (GBP) |
| Organisation | Juvenile Diabetes Research Foundation (JDRF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2007 |
| End | 04/2010 |
| Description | Stem Cell Initiative (Core Grant) |
| Amount | £1,143,873 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2006 |
| End | 12/2008 |
| Description | Stemstroke: Towards a Stem Cell Therapy for Stroke |
| Amount | £294,553 (GBP) |
| Funding ID | 37526 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2007 |
| End | 12/2009 |
| Description | Studentship Ms Amanda Anderson Rolf |
| Amount | £97,054 (GBP) |
| Funding ID | RG70550 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2013 |
| End | 09/2017 |
| Description | Summer Studentship for Magdelena Stasiulewicz |
| Amount | £2,500 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2010 |
| End | 08/2010 |
| Description | Supercharging platelets to prevent blood loss after trauma and regenerate hearts after heart attack |
| Amount | £60,000 (GBP) |
| Funding ID | M724 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 10/2020 |
| Description | SyBoSS Project - Systems Biology of Stem Cells and Reprogramming |
| Amount | £374,310 (GBP) |
| Funding ID | 242129 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 05/2010 |
| End | 05/2015 |
| Description | Synergistic Interaction Between the Master Regulator ASCL1 and Wnt Signaling Drives Neuroblastoma (Anna Philpott) |
| Amount | £58,920 (GBP) |
| Organisation | The Neuroblastoma Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 06/2018 |
| Description | THE TRANSCRIPTIONAL PROGRAMS OF MYELOPROLIFERATIVE NEOPLASMS |
| Amount | £689,196 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 01/2022 |
| Description | THE TRANSCRIPTIONAL PROGRAMS OF MYELOPROLIFERATIVE NEOPLASMS |
| Amount | £800,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 01/2022 |
| Description | The Discovery of future Neuro-therapeutic Molecules (NEUROscreen) |
| Amount | £195,139 (GBP) |
| Funding ID | 37766 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 07/2007 |
| End | 07/2010 |
| Description | The Pluripotent Stem Cells and Engineered Cell (PSEC) hub (Cedric Ghevaert) |
| Amount | £280,337 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 05/2023 |
| Description | The Road from Pluripotency to Lineage |
| Amount | £1,736,222 (GBP) |
| Funding ID | 091484 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2010 |
| End | 10/2015 |
| Description | The Stat3 pathway in Stem Cell Self renewal and the germline |
| Amount | £1,211,904 (GBP) |
| Funding ID | BB/G015678/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2009 |
| End | 05/2013 |
| Description | The engineered cell environment (Robin Franklin) |
| Amount | £460,906 (GBP) |
| Funding ID | MR/R015635/1 |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2021 |
| Description | The impact f genomic and microenvironmental factors on phenotype myeloproliferative neoplasms |
| Amount | £33,166 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 01/2018 |
| Description | Towards stem cell based therapies of leukemia: understanding the functional effects of preleukemic mutations on human haematopoietic stem cells (Elisa Laurenti) |
| Amount | £381,174 (GBP) |
| Organisation | British Council |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | Transcriptional control of cell fate decisions by chromatin remodelling proteins |
| Amount | £758,156 (GBP) |
| Funding ID | MR/R009759/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2020 |
| Description | Transcriptional programmes of myeloproliferative neoplasms |
| Amount | £1,489,605 (GBP) |
| Funding ID | A12765 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2022 |
| Description | Transplantation protocols to assess the ability of ES cell derived endodermal populations to differentiate towards pancreatic lineages |
| Amount | £26,596 (GBP) |
| Organisation | Juvenile Diabetes Research Foundation (JDRF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | UKRMP2 (PSEC) (Roger Barker) |
| Amount | £3,539,266 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 05/2023 |
| Description | UNDERSTANDING THE GENETIC ALTERATIONS THAT CAUSE LYMPHOMA |
| Amount | £62,543 (GBP) |
| Organisation | The Evelyn Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2022 |
| Description | Understanding The Contribution Of Notch1 Mutations To Treatment Response And Cellular Transformation In Cll |
| Amount | £220,287 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 04/2022 |
| Description | Understanding how the nurd complex assembles and functions in mouse embryonic stem cells |
| Amount | £20,160 (GBP) |
| Funding ID | MR/P019471/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 04/2022 |
| Description | Understanding mammalian interphase genome structure in mouse |
| Amount | £254,618 (GBP) |
| Funding ID | 206291/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 04/2022 |
| Description | Understanding the physical biology of adult blood stem cells |
| Amount | £1,304,348 (GBP) |
| Funding ID | 715371 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 04/2017 |
| End | 04/2022 |
| Description | WT Research Training Fellowship: Lay Ping Ong. Does Epicardium promote Cardiomyocyte Maturation and Cardiac Regeneration? (Sanjay Sinha) |
| Amount | £270,886 (GBP) |
| Funding ID | 203568/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | Wellcome 4-Year (1+3) PhD Programme in Stem Cell Biology & Medicine |
| Amount | £660,528 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2022 |
| Description | Wellcome Trust 4-Year Studentship - 5 year funding |
| Amount | £2,512,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2016 |
| Title | 'Cell Map' of early mammalian development |
| Description | technology to profile over 20,000 individual cells from the developing embryo to produce the first 'cell map' describing all of the major cell types present in early embryo development. The researchers used the map to identify an important new pathway involved in blood cell development and say the map could open up new avenues for medicine and drug development. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | The 'cell map' data also offers new drug development opportunities which could lead to future impacts.The identification of new pathways driving normal blood cell development has the potential to improve our ability to generate blood cells for these patients in the laboratory". This is a comprehensive and deep characterisation of cell types present in the mouse embryo at this critical stage of development, creating a rich resource for the community. The study illustrates the power of single cell based techniques to understand the development of organs such as the heart and brain. It could also help researchers to improve methods for creating mature, specialised cells from stem cells. |
| URL | https://www.nature.com/articles/s41556-017-0013-z |
| Title | Computer Model to simulate blood production from stem cells |
| Description | CSCI and Microsoft Research developed the first computer model to simulate the growth of blood cells from stem cells. This programme will help in the development of new treatments for blood cancer. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | The new computer model enables researchers to carry out simulated experiments in seconds that would normally take many weeks to perform in the lab. The model will dramatically speed up research into blood development and the genetic mutations that cause leukaemia. |
| URL | http://www.nature.com/articles/nbt.3154 |
| Description | Academic collaboration - Brian Huntly |
| Organisation | Queen Mary University of London |
| Department | Barts Cancer Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - academic collaboration |
| Collaborator Contribution | Collaboration with Paolo Gallipoli - academic collaboration |
| Impact | None yet |
| Start Year | 2019 |
| Description | Ana Cvejic - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ana Cvejic - Collaborative project |
| Collaborator Contribution | Collaborative research with Moritz Gerstung of the EMBL European Bioinformatics Institute. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Ana Cvejic - ISB-SIB |
| Organisation | Swiss Institute of Bioinformatics (SIB) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with David Gfeller; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2014 |
| Description | Ana Cvejic - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Sarah Teichmann; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2015 |
| Description | Ana Cvejic - Sanger (Macaulay) |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Ian Macaulay; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2015 |
| Description | Ana Cvejic - University of Cambridge (Haematology) |
| Organisation | University of Cambridge |
| Department | Cambridge Stem Cell Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Willem Ouwehand; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2012 |
| Description | Ana Cvejic - University of Manchester |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ana Cvejic; Co-author on paper. |
| Collaborator Contribution | Collaboration with Adam Hurlstone; Co-author on paper. |
| Impact | Co-author on paper. |
| Start Year | 2016 |
| Description | Ana Cvejic - Wellcome Sanger Institute |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI Ana Cvejic - Collaborative project |
| Collaborator Contribution | Collaboration with Omer Ali Bayraktar at the Wellcome Trust Sanger Institute. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Andrew McCaskis - UKRMP |
| Organisation | UK Regenerative Medicine Platform |
| Department | Engineered Cell Environment Hub |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | UK Regenerative Medicine Platform Hub - Engineered Cell Environment |
| Collaborator Contribution | UK Regenerative Medicine Platform Hub - Engineered Cell Environment |
| Impact | None yet |
| Start Year | 2018 |
| Description | Anna Philpott - CRUK CI |
| Organisation | Cancer Research UK Cambridge Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation. |
| Collaborator Contribution | Collaboration with Jason Carroll; Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation. |
| Impact | Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation. |
| Start Year | 2012 |
| Description | Anna Philpott - Gurdon |
| Organisation | University of Cambridge |
| Department | Gurdon Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Anna Philpott;; Transcriptional dynamics. |
| Collaborator Contribution | Collaboration with John Gurdon; Transcriptional dynamics. |
| Impact | Transcriptional dynamics. |
| Start Year | 2011 |
| Description | Anna Philpott - Harvard Medical School |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Mathematical modelling of transcriptional dynamics. |
| Collaborator Contribution | Collaboration with Jeremy Gunawardena; Mathematical modelling of transcriptional dynamics. |
| Impact | Mathematical modelling of transcriptional dynamics. |
| Start Year | 2010 |
| Description | Anna Philpott - Harvard Medical School |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Mathematical modelling of transcriptional dynamics. |
| Collaborator Contribution | Collaboration with Jeremy Gunawardena; Mathematical modelling of transcriptional dynamics. |
| Impact | Mathematical modelling of transcriptional dynamics. |
| Start Year | 2010 |
| Description | Anna Philpott - Harvard Stem Cell Institute |
| Organisation | Harvard University |
| Department | Harvard Stem Cell Institute |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Anna Philpott; Collaborator on an MRC grant on islet cell formation in the pancreas. |
| Collaborator Contribution | Collaboration with Doug Melton.; Collaborator on an MRC grant on islet cell formation in the pancreas. |
| Impact | Collaborator on an MRC grant on islet cell formation in the pancreas. |
| Start Year | 2013 |
| Description | Austin Smith - AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Austin Smith; Advisory Board. |
| Collaborator Contribution | Collaboration with Lorenz Mayr; Advisory Board. |
| Impact | Advisory Board. |
| Start Year | 2015 |
| Description | Austin Smith - Cell Therapy Catapult |
| Organisation | Cell Therapy Catapult |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Austin Smith; Advisory Board. |
| Collaborator Contribution | Collaboration with Johan Hyllner; Adviosry Board. |
| Impact | Advisory Board. |
| Start Year | 2014 |
| Description | Austin Smith - Microsoft Research |
| Organisation | Microsoft Research |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Austin Smith; Computational Modelling. |
| Collaborator Contribution | Collaboration with Stephen Emmott and Sara-Jane Dunn; Computational modelling. |
| Impact | Computational modelling; Joint publications. |
| Start Year | 2013 |
| Description | Austin Smith - PSCP |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Austin Smith; The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Collaborator Contribution | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Impact | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Start Year | 2013 |
| Description | Austin Smith - PSCP |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Austin Smith; The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Collaborator Contribution | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Impact | The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies. |
| Start Year | 2013 |
| Description | Austin Smith - Ramiro Alberio |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Pluripotency in sheep and pig |
| Collaborator Contribution | Pluripotency in sheep and pig |
| Impact | None yet |
| Start Year | 2018 |
| Description | Austin Smith - StemCell Technologies |
| Organisation | Stemcell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | CSCI PI: Austin Smith; Partner in EC project plus licensing agreement. |
| Collaborator Contribution | Collaboration with Sharon Louis and Allen Eaves; Partner in EC project plus licensing agreement. |
| Impact | Partner in EC project plus licensing agreement. |
| Start Year | 2014 |
| Description | BK Koo - Sanger |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Bon-Kyoung Koo; We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data. |
| Collaborator Contribution | Collaboration with John Marioni; We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data. |
| Impact | We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data. |
| Start Year | 2016 |
| Description | BK Koo - University Carl Gustav Carus |
| Organisation | University Hospital Carl Gustav Carus Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bon-Kyoung Koo; ERC Starting Grant. |
| Collaborator Contribution | Collaboration with Daniel Stange. |
| Impact | Joint meeting for developing placenta and endometrium organoids. |
| Start Year | 2014 |
| Description | BK Koo - University of Cambridge (Centre for Trophoblast Research) |
| Organisation | University of Cambridge |
| Department | Department of Haematology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bon-Kyoung Koo; Joint meeting for developing placenta and endometrium organoids. |
| Collaborator Contribution | Collaboration with Graham Burton and Ashley Moffett; Joint meeting for developing placenta and endometrium organoids. |
| Impact | Joint meeting for developing placenta and endometrium organoids. |
| Start Year | 2014 |
| Description | Ben Simons - Danstem |
| Organisation | University of Copenhagen |
| Department | Psychiatric Center Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Development of the mouse intestinal epithelium and development of epidermal appendages. |
| Collaborator Contribution | Collaboration with Kim Jensen; Development of the mouse intestinal epithelium and development of epidermal appendages. |
| Impact | Development of the mouse intestinal epithelium and development of epidermal appendages. |
| Start Year | 2016 |
| Description | Ben Simons - Hospital for Sick Children |
| Organisation | The Hospital for Sick Children (SickKids) |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Ben Simons; Dynamics of tumour propagating cells in medullablastoma and gioblastoma. |
| Collaborator Contribution | Collaboration with Peter Dirks; Dynamics of tumour propagating cells in medullablastoma and gioblastoma. |
| Impact | Dynamics of tumour propagating cells in medullablastoma and gioblastoma. |
| Start Year | 2013 |
| Description | Ben Simons - Hubrecht Institute |
| Organisation | Royal Netherlands Academy of Arts and Sciences |
| Department | Hubrecht Institute |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of the adult subventricular zone. |
| Collaborator Contribution | Collaboration with Hans Clevers; Maintenance of the adult subventricular zone. |
| Impact | Maintenance of the adult subventricular zone. |
| Start Year | 2010 |
| Description | Ben Simons - Hubrecht Institute |
| Organisation | Royal Netherlands Academy of Arts and Sciences |
| Department | Hubrecht Institute |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of the intestinal epithelium and development of the mammary epithelium. |
| Collaborator Contribution | Collaboration with Jacco van Rheenen; Maintenance of the intestinal epithelium and development of the mammary epithelium. |
| Impact | Maintenance of the intestinal epithelium and development of the mammary epithelium. |
| Start Year | 2013 |
| Description | Ben Simons - John Hopkins Medical School |
| Organisation | Johns Hopkins University |
| Department | School of Medicine Johns Hopkins |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of the adult subgranular zone. |
| Collaborator Contribution | Collaboration with Hongjun Song; Maintenance of the adult subgranular zone. |
| Impact | Maintenance of the adult subgranular zone. |
| Start Year | 2012 |
| Description | Ben Simons - Memorial Sloane Kettering Cancer Center |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Development of mouse neocortex. |
| Collaborator Contribution | Collaboration with Songhai Shi; Development of mouse neocortex. |
| Impact | Development of mouse neocortex. |
| Start Year | 2013 |
| Description | Ben Simons - National Institute for Basic Biology |
| Organisation | Ministry of the Environment |
| Department | National Institute for Basic Biology (NIBB) |
| Country | Japan |
| Sector | Public |
| PI Contribution | CSCI PI: Ben Simons; Spermatogenesis in mouse. |
| Collaborator Contribution | Collaboration with Shosei Yoshida; Spermatogenesis in mouse. |
| Impact | Spermatogenesis in mouse. |
| Start Year | 2009 |
| Description | Ben Simons - Universite Libre de Bruxelles |
| Organisation | University Libre Bruxelles (Université Libre de Bruxelles ULB) |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Mechanisms of development and tumour initiation in epidermis. |
| Collaborator Contribution | Collaboration with Cedric Blanpain; Mechanisms of development and tumour initiation in epidermis. |
| Impact | Mechanisms of development and tumour initiation in epidermis. Several publications. |
| Start Year | 2011 |
| Description | Ben Simons - University College London |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Maintenance of human airways. |
| Collaborator Contribution | Collaboration with Samuel Janes; Maintenance of human airways. |
| Impact | Maintenance of human airways. |
| Start Year | 2012 |
| Description | Ben Simons - University of Cambridge (PDN) |
| Organisation | University of Cambridge |
| Department | Department of Psychology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Ben Simons; Development of zebrafish retina. |
| Collaborator Contribution | Collaboration with William Harris; Development of zebrafish retina. |
| Impact | Development of zebrafish retina. |
| Start Year | 2011 |
| Description | Bertie Gottgens - Allon Klein |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Single cell studies |
| Collaborator Contribution | Single cell studies |
| Impact | None yet |
| Start Year | 2018 |
| Description | Bertie Gottgens - Autolus |
| Organisation | Autolus Limited |
| Department | Autolus |
| Country | Poland |
| Sector | Private |
| PI Contribution | CSCI PI: Bertie Gottgens; Single cell genomics analysis of CAR-T cells. |
| Collaborator Contribution | Collaboration with Nina Kotsopoulou; Single cell genomics analysis of CAR-T cells. |
| Impact | Single cell genomics analysis of CAR-T cells. |
| Start Year | 2016 |
| Description | Bertie Gottgens - Baylor College of Medicine |
| Organisation | Baylor College of Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Peggy Goodell; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2014 |
| Description | Bertie Gottgens - Centro de Medicina Regenerativa de Barcelona |
| Organisation | Center of Regenerative Medicine in Barcelona |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Bertie Gottgens; RNA-Seq. |
| Collaborator Contribution | Collaboration with Alessandra Giorgetti; RNA-seq |
| Impact | RNA-seq. |
| Start Year | 2016 |
| Description | Bertie Gottgens - David Bryder |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens - Joint research paper. |
| Collaborator Contribution | Collaboration with David Bryder - Joint research paper. |
| Impact | Joint research paper. |
| Start Year | 2017 |
| Description | Bertie Gottgens - Dresden |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens. |
| Collaborator Contribution | Collaboration with Claudia Waskow. |
| Impact | None yet. |
| Start Year | 2016 |
| Description | Bertie Gottgens - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with John Marioni; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2015 |
| Description | Bertie Gottgens - Elaine Dzierzak |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Single cell studies. Joint research paper |
| Collaborator Contribution | Single cell studies. Joint research paper |
| Impact | Joint research paper |
| Start Year | 2018 |
| Description | Bertie Gottgens - Fiona Gribble |
| Organisation | University of Cambridge |
| Department | Department of Clinical Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens - Joint research paper. |
| Collaborator Contribution | Collaboration with Fiona Gribble - joint research paper. |
| Impact | Joint research paper. |
| Start Year | 2017 |
| Description | Bertie Gottgens - GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Bertie Gottgens; Single cell profiling of gene therapy products. |
| Collaborator Contribution | Single cell profiling of gene therapy products. |
| Impact | Single cell profiling of gene therapy products. |
| Start Year | 2016 |
| Description | Bertie Gottgens - Hui Zhang |
| Organisation | Chinese Academy of Sciences |
| Department | Shenzhen Institute of Advanced Integration Technology |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Training in research techniques |
| Collaborator Contribution | Training in research techniques |
| Impact | None yet |
| Start Year | 2018 |
| Description | Bertie Gottgens - KJ Patel |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Laboratory of Molecular Biology (LMB) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Single cell studies |
| Collaborator Contribution | Single cell studies |
| Impact | None yet |
| Start Year | 2018 |
| Description | Bertie Gottgens - Larissa Carnevalli |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Joint research project on Acute Myeloid Leukaemia |
| Collaborator Contribution | Joint research project on Acute Myeloid Leukaemia |
| Impact | None yet. |
| Start Year | 2018 |
| Description | Bertie Gottgens - Novo Nordisk |
| Organisation | Novo Nordisk |
| Country | Denmark |
| Sector | Private |
| PI Contribution | Study (covered by CDA) of embryonic blood cell development |
| Collaborator Contribution | Study (covered by CDA) of embryonic blood cell development |
| Impact | None yet |
| Start Year | 2019 |
| Description | Bertie Gottgens - Ross Hardison |
| Organisation | Penn State University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint National Institutes of Health grant |
| Collaborator Contribution | Collaboration with Ross Hardison - Joint National Institutes of Health grant. |
| Impact | Joint National Institutes of Health grant |
| Start Year | 2017 |
| Description | Bertie Gottgens - Sheba Medical Centre |
| Organisation | Sheba Medical Centre |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Shai Izraeli; Joint research papers. |
| Impact | Joint research papers. |
| Description | Bertie Gottgens - Thomas Mercher |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens - Single cell analysis |
| Collaborator Contribution | Collaboration with Thomas Mercher - Single cell analysis |
| Impact | Single cell analysis. |
| Start Year | 2017 |
| Description | Bertie Gottgens - University of Birmigham |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Joint research papers. Joint BBSRC LoLa Award. |
| Collaborator Contribution | Collaboration with Constanze Bonifer, Georges Lacaud and Valeirie Kouskoff; Joint research papers. Joint BBSRC LoLa Award |
| Impact | Joint research papers. Joint BBSRC LoLa Award. |
| Start Year | 2011 |
| Description | Bertie Gottgens - University of Birmigham |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Joint research papers. Joint BBSRC LoLa Award. |
| Collaborator Contribution | Collaboration with Constanze Bonifer, Georges Lacaud and Valeirie Kouskoff; Joint research papers. Joint BBSRC LoLa Award |
| Impact | Joint research papers. Joint BBSRC LoLa Award. |
| Start Year | 2011 |
| Description | Bertie Gottgens - University of California San Francisco |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint publication. |
| Collaborator Contribution | Collaboration with Emanuelle Passegue; Joint publication. |
| Impact | Joint publication. |
| Start Year | 2016 |
| Description | Bertie Gottgens - University of Cambridge (Genetics) |
| Organisation | University of Cambridge |
| Department | Department of Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Boris Adryan; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2015 |
| Description | Bertie Gottgens - University of New South Wales |
| Organisation | University of New South Wales |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaborations with John Pimanda; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2007 |
| Description | Bertie Gottgens - University of Oxford |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Single cell analysis. |
| Collaborator Contribution | Collaboration with John Todd; Single cell analysis. |
| Impact | Single cell analysis. None yet. |
| Start Year | 2016 |
| Description | Bertie Gottgens - Vrifje University of Amsterdam |
| Organisation | Free University of Amsterdam |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Nicola Bonzanni; Joint research papers |
| Impact | Joint research papers. |
| Start Year | 2008 |
| Description | Bertie Gottgens - WIMM |
| Organisation | University of Oxford |
| Department | Weatherall Institute of Molecular Medicine (WIMM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Bertie Gottgens; Joint research papers. |
| Collaborator Contribution | Collaboration with Marella de Brujin; Joint research papers. |
| Impact | Joint research papers. |
| Start Year | 2007 |
| Description | Beta Cell Therapy / SCI |
| Organisation | JDRF Center for Beta Cell Therapy in Diabetes |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | Beta Cell Therapy in Diabetes - European Framework 7 |
| Collaborator Contribution | Beta Cell Therapy in Diabetes - European Framework 7 |
| Impact | n/a |
| Start Year | 2010 |
| Description | Brian Hendrich - EMBL |
| Organisation | European Molecular Biology Laboratory |
| Department | EMBL-Grenoble |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaboration on NuRD structure. Co-PI on EU FP7 Grant. |
| Collaborator Contribution | Collaboration with Imre Berger; Collaboration on NuRD structure. Co-PI on EU FP7 Grant. |
| Impact | Collaboration on NuRD structure. Co-PI on EU FP7 Grant. |
| Start Year | 2013 |
| Description | Brian Hendrich - European Institute of Oncology |
| Organisation | European Institute of Oncology (IEO) |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaborative small molecule screens. Co-PI on EU FP7 grant. |
| Collaborator Contribution | Collaboration with Saverio Minucci; Collaborative small molecule screens. Co-PI on EU FP7 grant. |
| Impact | Collaborative small molecule screens. Co-PI on EU FP7 grant. |
| Start Year | 2012 |
| Description | Brian Hendrich - MRC CSC |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Clinical Sciences Centre (CSC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | CSCI PI: Brian Hendrich; Joint authored paper submitted. |
| Collaborator Contribution | Collaboration with Matthias Merkenschlager; Joint authored paper submitted. |
| Impact | Joint authored paper submitted. |
| Start Year | 2015 |
| Description | Brian Hendrich - Sandra Hake |
| Organisation | Justus Liebig University Giessen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich - Investigation of Mta protein function: one joint publication in preparation |
| Collaborator Contribution | Collaboration with Sandra Hake - Investigation of Mta protein function: one joint publication in preparation |
| Impact | Investigation of Mta protein function: one joint publication in preparation. |
| Start Year | 2016 |
| Description | Brian Hendrich - Trinity College Dublin |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Function of chromatin remodellers in development and cancer. Joint grant application planned. |
| Collaborator Contribution | Collaboration with Adrian Bracken; Function of chromatin remodellers in development and cancer. Joint grant application planned. |
| Impact | Function of chromatin remodellers in development and cancer. Joint grant application planned. |
| Start Year | 2015 |
| Description | Brian Hendrich - University Medical Centre Utrecht |
| Organisation | University Medical Center Utrecht (UMC) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published. |
| Collaborator Contribution | Collaboration with Michiel Vermeulen; Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published. |
| Impact | Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published |
| Start Year | 2013 |
| Description | Brian Hendrich - University of Cambridge (Biochemistry - Lilley) |
| Organisation | University of Cambridge |
| Department | Department of Chemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Collaborative research, named on her grant applications. |
| Collaborator Contribution | Collaboration with Kathryn Lilley; Collaborative research, named on her grant applications. |
| Impact | Collaborative research, named on her grant applications. |
| Start Year | 2014 |
| Description | Brian Hendrich - University of Cambridge (Biochemistry) |
| Organisation | University of Cambridge |
| Department | Department of Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published. |
| Collaborator Contribution | Collaboration with Ernest Laue; One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published. |
| Impact | One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published. |
| Start Year | 2009 |
| Description | Brian Hendrich - University of Dundee |
| Organisation | University of Dundee |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Greg Findlay of the University of Dundee |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Edinburgh |
| Organisation | University of Edinburgh |
| Department | Centre for Discovery Brain Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with John Mason of the University of Edinburgh's Centre for Discovery Brain Sciences. |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Joint research efforts, one joint group meeting in Edinburgh, discussing grant options. |
| Collaborator Contribution | Collaboration with Adrian Bird; Joint research efforts, one joint group meeting in Edinburgh, discussing grant options. |
| Impact | Joint research efforts, one joint group meeting in Edinburgh, discussing grant options. |
| Start Year | 2014 |
| Description | Brian Hendrich - University of Kumamoto |
| Organisation | University of Kumamoto |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Mice supplied, one joint paper published. |
| Collaborator Contribution | Collaboration with Ryuichi Nishinakamura; Mice supplied, one joint paper published. |
| Impact | Mice supplied, one joint paper published. |
| Start Year | 2012 |
| Description | Brian Hendrich - University of Oslo |
| Organisation | University of Oslo |
| Department | Institute of Basic Medical Sciences |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Gareth Sullivan of the University of Oslo's Institute of Basic Medical Sciences. |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Sussex |
| Organisation | University of Sussex |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Hendrich; Investigating DNA repair function of CHD4. |
| Collaborator Contribution | Collaboration with Jessica Downs; Investigating DNA repair function of CHD4. |
| Impact | Investigating DNA repair function of CHD4. |
| Start Year | 2014 |
| Description | Brian Hendrich - Washington University in St. Louis |
| Organisation | Washington University in St Louis |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Sabine Dietman of the Washington University (St Louis) School of Medicine. |
| Impact | Application outcome unknown |
| Start Year | 2020 |
| Description | Brian Huntly - Babraham Institute |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaborative project with Wolf Reik of Babraham Institute's Epigenetics lab. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - Centre for Genomic Regulation |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaboration with Marc Marti-Renom of the Centre for Genomic Regulation |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - David Adams |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI: Brian Huntly - Joint papers |
| Collaborator Contribution | Collaboration with David Adams - joint papers. |
| Impact | Joint papers. |
| Start Year | 2017 |
| Description | Brian Huntly - Denis Calado, Jude Fitzgibbon, Jessica Okusun |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - academic collaboration |
| Collaborator Contribution | Collaboration with Denis Calado, Jude Fitzgibbon, Jessica Okusun. |
| Impact | Academic collaboration - ongoing. |
| Start Year | 2017 |
| Description | Brian Huntly - GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly; Mechanistic, pre-clinical investigation of BET inhibitors. |
| Collaborator Contribution | Collaboration with Rab Prinjha; Mechanistic, pre-clinical investigation of BET inhibitors. |
| Impact | Mechanistic, pre-clinical investigation of BET inhibitors. |
| Start Year | 2013 |
| Description | Brian Huntly - GSK Cancer Epigenetics DPU |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly; Translational collaboration re experimental therapeutics. |
| Collaborator Contribution | Collaboration with Peter Tumino; Translational collaboration re experimental therapeutics. |
| Impact | Translational collaboration re experimental therapeutics. |
| Start Year | 2012 |
| Description | Brian Huntly - Institut Gustave Roussy |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaboration with Thomas Mercher of l'Institut Gustave Roussy |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - John Pimanda |
| Organisation | University of New South Wales |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - Joint papers. |
| Collaborator Contribution | Collaboration with John Pimanda - joint papers. |
| Impact | Joint papers. |
| Start Year | 2015 |
| Description | Brian Huntly - Kings College London |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with Cameron Osbourne; Academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2014 |
| Description | Brian Huntly - MRC Cancer Unit |
| Organisation | University of Cambridge |
| Department | MRC Cancer Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with Christian Frezza; Academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2012 |
| Description | Brian Huntly - Ming Du |
| Organisation | University of Cambridge |
| Department | Department of Pathology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - Joint papers |
| Collaborator Contribution | Collaboration with Ming-Qing Du - joint papers. |
| Impact | Joint papers. |
| Start Year | 2017 |
| Description | Brian Huntly - Nigel Brooks |
| Organisation | CellCentric Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly - Investigation of CREBBP/p300 inhibitor. |
| Collaborator Contribution | Collaboration with Nigel Brooks - Investigation of CREBBP/p300 inhibitor. |
| Impact | Investigation of CREBBP/p300 inhibitor. |
| Start Year | 2017 |
| Description | Brian Huntly - Pfizer |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Brian Huntly; Translational collaboration re experimental therapeutics. |
| Collaborator Contribution | Collaboration with Kevin Lee; Translational collaboration re experimental therapeutics. |
| Impact | Translational collaboration re experimental therapeutics. |
| Start Year | 2012 |
| Description | Brian Huntly - Radek Skoda |
| Organisation | University Hospital Basel |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | CSCI PI: Brian Huntly - Academic collaboration |
| Collaborator Contribution | Collaboration with Radek Skoda - academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2017 |
| Description | Brian Huntly - Ulrich Steidl |
| Organisation | Albert Einstein College of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly - academic collaboration. |
| Collaborator Contribution | Collaboration with Ulrich Steidl - academic collaboration. |
| Impact | Academic collaboration. |
| Start Year | 2017 |
| Description | Brian Huntly - University of Cambridge (Gurdon) |
| Organisation | National Institute for Health Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with Tony Kouzarides. |
| Impact | Academic collaboration. |
| Start Year | 2010 |
| Description | Brian Huntly - University of Copenhagen |
| Organisation | University of Copenhagen |
| Department | Department of Veterinary Disease Biology |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Generation of acetylation target datasets. |
| Collaborator Contribution | Collaboration with Chuna Ram Choudhary; Generation of acetylation target datasets. |
| Impact | Generation of acetylation target datasets. |
| Start Year | 2013 |
| Description | Brian Huntly - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with KAtrin Ottersbach; Academic collaboration. |
| Impact | Joint paper; Academic collaboration. |
| Start Year | 2008 |
| Description | Brian Huntly - University of Edinburgh |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Brian Huntly; Academic collaboration. |
| Collaborator Contribution | Collaboration with KAtrin Ottersbach; Academic collaboration. |
| Impact | Joint paper; Academic collaboration. |
| Start Year | 2008 |
| Description | Brian Huntly - University of Navarra |
| Organisation | University of Navarra Clinic |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project and joint grant application |
| Collaborator Contribution | Collaboration and joint grant application with Felipe Prosper of University of Navarra Clinic. |
| Impact | Outcomes expected later in 2021 |
| Start Year | 2020 |
| Description | Cedric Ghevaert - AstraZeneca |
| Organisation | AstraZeneca |
| Department | AstraZeneca Sweden |
| Country | Sweden |
| Sector | Private |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ryan Hicks at AstraZeneca Sweden involving university stem cells. |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - DefiniGEN |
| Organisation | DefiniGEN |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI: Cedric Ghevaert; Discussions around licence for megakaryocyte patent. |
| Collaborator Contribution | Collaboration with Marcus Yeo; Discussions around licence for megakaryocyte patent. |
| Impact | Discussions around licence for megakaryocyte patent. |
| Start Year | 2016 |
| Description | Cedric Ghevaert - Platelet Biogenesis |
| Organisation | University of Hawaii |
| Department | Institute for Biogenesis Research |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Cedric Ghevaert; Discussions around licence for megakaryocyte patent. |
| Collaborator Contribution | Collaboration with Jonathon Thon; Discussions around licence for megakaryocyte patent. |
| Impact | Discussions around licence for megakaryocyte patent. |
| Start Year | 2016 |
| Description | Cedric Ghevaert - Platod |
| Organisation | PLATOD |
| Country | France |
| Sector | Private |
| PI Contribution | CSCI PI: Cedric Ghevaert. Discussions around licence for megakaryocyte patent. |
| Collaborator Contribution | Collaboration with Dominic Baruch; Discussions around licence for megakaryocyte patent. |
| Impact | Discussions around licence for megakaryocyte patent. |
| Start Year | 2016 |
| Description | Cedric Ghevaert - Rockend, LTD |
| Organisation | University of Cambridge |
| Department | Milner Therapeutics Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Shaun Foy and Rodger Novak of Rockend, Ltd, titled "Production of platelet-like particles in vitro for therapeutics." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - Ruth Cameron and Serena Best |
| Organisation | University of Cambridge |
| Department | Department of Materials Science & Metallurgy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Cedric Ghevaert; Bioscaffold |
| Collaborator Contribution | Collaboration with Ruth Cameron and Serena Best - bioscaffold |
| Impact | Bioscaffold |
| Start Year | 2014 |
| Description | Cedric Ghevaert - University College London - University of Edinburgh |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University College London - University of Edinburgh |
| Organisation | University of Edinburgh |
| Department | MRC Centre for Regenerative Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University of Bristol |
| Organisation | University of Bristol |
| Department | School of Physiology, Pharmacology and Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Alastair Poole of University of Bristol titled "Biogenesis and Bioengineering of Human Platelets." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University of Cambridge Material Science |
| Organisation | University of Cambridge |
| Department | Department of Materials Science & Metallurgy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Sohini Kar-Narayan of the University of Cambridge Department of Materials Science & Metallurgy. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | University of Sheffield |
| Department | Department of Biomedical Science |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Dan Hodso - Markus Meuler |
| Organisation | PhoreMost |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Collaboration with Phoremost to use human protein domain library to screen to identify therapeutic strategies to target the OCT2-OCA-B interface. |
| Collaborator Contribution | Collaboration with Phoremost to use human protein domain library to screen to identify therapeutic strategies to target the OCT2-OCA-B interface. |
| Impact | None yet |
| Start Year | 2018 |
| Description | Dan Hodson - Babraham |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Dan Hodson; Collaborative research. |
| Collaborator Contribution | Collaboration with David Turner; Collaborative research. |
| Impact | None yet |
| Start Year | 2013 |
| Description | David Kent - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Machine Learning and quantitative biology. |
| Collaborator Contribution | Collaboration with Florian Buttner;Machine Learning and quantitative biology. |
| Impact | Machine Learning and quantitative biology. |
| Start Year | 2015 |
| Description | David Kent - GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CSCI PI: David Kent; GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology. |
| Collaborator Contribution | Collaboration with Armin Sepp; GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology. |
| Impact | GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology. |
| Start Year | 2016 |
| Description | David Kent - Leon Lin |
| Organisation | Stemcell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | STEMCELL Technologies reagent testing |
| Collaborator Contribution | STEMCELL Technologies reagent testing |
| Impact | None yet |
| Start Year | 2018 |
| Description | David Kent - Memorial Sloan Kettering |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Sequencing and clinical genomics. |
| Collaborator Contribution | Collaboration with Elli Papaemmanuil; Sequencing and clinical genomics. |
| Impact | Sequencing and clinical genomics. |
| Start Year | 2013 |
| Description | David Kent - Mike Stratton |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Genomics signatures in cancer |
| Collaborator Contribution | Genomics signatures in cancer |
| Impact | None yet. |
| Start Year | 2018 |
| Description | David Kent - University of British Columbia |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Reagents and knowledge transfer. |
| Collaborator Contribution | Collaboration with Connie Eaves; Reagents and knowledge transfer. |
| Impact | Reagents and knowledge transfer. |
| Description | David Kent - Weizmann Institute |
| Organisation | Weizmann Institute of Science |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CSCI PI: David Kent; Asymmetric Division of HSCs. |
| Collaborator Contribution | Collaborationwith Tsvee Lapidot; Asymmetric Division of HSCs. |
| Impact | Asymmetric Division of HSCs. |
| Start Year | 2015 |
| Description | David Rowitch - StemCells Inc |
| Organisation | StemCells, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | CSCI PI: David Rowitch; Collaborative research. |
| Collaborator Contribution | Collaborative research. |
| Impact | Collaborative research. |
| Start Year | 2010 |
| Description | Deep Sequencing |
| Organisation | Radboud University Nijmegen Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Deep Sequencing |
| Collaborator Contribution | Deep Sequencing |
| Impact | n/a |
| Start Year | 2011 |
| Description | EBI / SCI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Deep sequence analysis |
| Collaborator Contribution | Deep sequence analysis |
| Impact | Publication: Identification of the missing pluripotency mediator downstream of leukaemia inhibitory |
| Start Year | 2011 |
| Description | ESTOOLS |
| Organisation | Academy of Sciences of the Czech Republic |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Babraham Institute |
| Department | Stem Cell Sciences UK Ltd |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Bellvitge Biomedical Research Institute |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Hebrew University of Jerusalem |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Netherlands Cancer Institute (NKI) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Stem Cell Technologies |
| Country | Canada |
| Sector | Private |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Tampere University of Technology |
| Country | Finland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Basel |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Bonn |
| Department | Medical Centre Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Helsinki |
| Country | Finland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | ESTOOLS |
| Organisation | University of Turku |
| Country | Finland |
| Sector | Academic/University |
| PI Contribution | PI |
| Collaborator Contribution | 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI |
| Impact | Not Given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Babraham Institute |
| Department | Stem Cell Sciences UK Ltd |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | European Molecular Biology Laboratory |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | NeuroNova AB |
| Country | Sweden |
| Sector | Private |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | NsGene A/S |
| Country | Denmark |
| Sector | Private |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Pasteur Institute, Paris |
| Country | France |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | San Raffaele Hospital |
| Department | Stem Cell Research Institute |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | Swiss Federal Institute of Technology in Lausanne (EPFL) |
| Country | Switzerland |
| Sector | Public |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Bonn |
| Department | Medical Centre Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | EUROSTEMCELL |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Austin Smith was the coordinator of this collaboration. |
| Collaborator Contribution | xxx |
| Impact | Not given |
| Start Year | 2006 |
| Description | Elisa Laurenti - EPFL |
| Organisation | Swiss Federal Institute of Technology in Lausanne (EPFL) |
| Country | Switzerland |
| Sector | Public |
| PI Contribution | CSCI PI: Elisa Laurenti; Joint publications. |
| Collaborator Contribution | Collaboration with Didier Trono; Joint publications. |
| Impact | Joint publications. |
| Start Year | 2007 |
| Description | Elisa Laurenti - Hitoshi Takizawa |
| Organisation | Kumamoto University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti - Studying adult human haematopoietic stem cells using a humanised bone marrow environment. |
| Collaborator Contribution | Collaboration with Hitoshi Takizawa - Studying adult human haematopoietic stem cells using a humanised bone marrow environment. |
| Impact | Studying adult human haematopoietic stem cells using a humanised bone marrow environment. |
| Start Year | 2017 |
| Description | Elisa Laurenti - Liran Shlush |
| Organisation | Weizmann Institute of Science |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti - Functional effects of preleukaemic mutations on human haematopoietic stem cells. |
| Collaborator Contribution | Collaboration with Liran Shlush - Functional effects of preleukaemic mutations on human haematopoietic stem cells. |
| Impact | Functional effects of preleukaemic mutations on human haematopoietic stem cells. |
| Start Year | 2017 |
| Description | Elisa Laurenti - Max Planck Institute of Immunobiology and Epigenetics |
| Organisation | Max Planck Society |
| Department | Max Planck Institute of Immunobiology and Epigenetics |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI Elisa Laurenti - Collaborative project |
| Collaborator Contribution | Collaboration with Nina Cabezas-Wallscheid entitled "Molecular regulation of human haematopoietic stem cell quiescence." |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Elisa Laurenti - Peter Campbell |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Age-related changes in human haematopoietic stem cells at single cell and population levels |
| Collaborator Contribution | Age-related changes in human haematopoietic stem cells at single cell and population levels |
| Impact | None yet |
| Start Year | 2018 |
| Description | Elisa Laurenti - Universite Paris Descartes |
| Organisation | University of Paris - Descartes |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; The transcriptional programmes of T-Acute Lymphoblastic Leukaemia. |
| Collaborator Contribution | Collaboration with Elizabeth Macintyre; The transcriptional programmes of T-Acute Lymphoblastic Leukaemia. |
| Impact | The transcriptional programmes of T-Acute Lymphoblastic Leukaemia. |
| Start Year | 2015 |
| Description | Elisa Laurenti - University Health Network |
| Organisation | University Health Network (UHN) |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; Joint publications. |
| Collaborator Contribution | Collaboration with John Dick; Joint publications. |
| Impact | Joint publications. |
| Start Year | 2014 |
| Description | Elisa Laurenti - University of Cambridge (Haematology) |
| Organisation | UK Clinical Research Collaboration |
| Department | Centre for Diet and Activity Research (CEDAR) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; Effects of inflammation on HSC; study of adult human HSC. |
| Collaborator Contribution | Collaboration with Willem Ouwehand and Mattia Frontini; Effects of inflammation on HSC; study of adult human HSC. |
| Impact | Effects of inflammation on HSC; study of adult human HSC. |
| Start Year | 2014 |
| Description | Elisa Laurenti - University of Cambridge (Surgery) |
| Organisation | University of Cambridge |
| Department | Department of Engineering |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI: Elisa Laurenti; Study of adult human HSC and their cryopreservation. |
| Collaborator Contribution | Collaboration with Kouroush Saeb-Parsy.; Study of adult human HSC and their cryopreservation. |
| Impact | Study of adult human HSC and their cryopreservation. |
| Start Year | 2015 |
| Description | Elisa Laurenti, Bertie Gottgens - Muzlifah Haniffa |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Decoding the blood and immune systems development during human fetal liver haematopoiesis |
| Collaborator Contribution | Decoding the blood and immune systems development during human fetal liver haematopoiesis |
| Impact | None yet |
| Start Year | 2018 |
| Description | Euratrans |
| Organisation | Academy of Sciences of the Czech Republic |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Alternative Energies and Atomic Energy Commission (CEA) |
| Country | France |
| Sector | Public |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | European Molecular Biology Laboratory |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Helmholtz Association of German Research Centres |
| Department | The Max Delbrück Center for Molecular Medicine (MDC) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Max Planck Society |
| Department | Max Planck Institute of Biochemistry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Medical College of Wisconsin |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Research Network Services (RNSL) Ltd Berlin |
| Country | Germany |
| Sector | Private |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Royal Institute of Technology |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | Royal Netherlands Academy of Arts and Sciences |
| Department | Hubrecht Institute |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Groningen |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Kyoto |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | Euratrans |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin Smith is a PI on this collaboration. |
| Collaborator Contribution | European large-scale functional genomics in the rat for translational research |
| Impact | http://www.euratrans.eu/ |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Dando, Weiss & Colucci Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | JDRF Center for Beta Cell Therapy in Diabetes |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Life and Brain GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Galway |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |
| Description | EuroStemCell |
| Organisation | University of Milan |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Austin is a principal investigator for this collaboration |
| Collaborator Contribution | EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh |
| Impact | www.eurostemcell.org |
| Start Year | 2010 |